Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1978 Nov;6(5):421–427. doi: 10.1111/j.1365-2125.1978.tb04606.x

Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype.

K Carr, J A Oates, A S Nies, R L Woosley
PMCID: PMC1429553  PMID: 728285

Abstract

1 A rapid, accurate and convenient technique for determination of acetylator phenotype of patients or subjects has not been available for routine clinical application. 2 An improved method for rapid and convenient determination of acetylator phenotype is described. 3 The plasma concentrations of dapsone (DDS) and monoacetyldapsone (MAD) were measured 3 h after a single oral 100 mg dose of dapsone using a specific and sensitive high performance liquid chromatographic assay. 4 The plasma concentration ratio of monoacetyldapsone to dapsone can accurately assess acetylator phenotype in patients or subjects. 5 The clinical applications for this method are discussed.

Full text

PDF
421

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón-Segovia D., Fishbein E., Alcalá H. Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid treatment. Arthritis Rheum. 1971 Nov-Dec;14(6):748–752. doi: 10.1002/art.1780140610. [DOI] [PubMed] [Google Scholar]
  2. Carr K., Woosley R. L., Oates J. A. Simultaneous quantification of procainamide and N-acetylprocainamide with high-performance liquid chromatography. J Chromatogr. 1976 Dec 22;129:363–368. doi: 10.1016/s0021-9673(00)87796-1. [DOI] [PubMed] [Google Scholar]
  3. DEVADATTA S., GANGADHARAM P. R., ANDREWS R. H., FOX W., RAMAKRISHNAN C. V., SELKON J. B., VELU S. Peripheral neuritis due to isoniazid. Bull World Health Organ. 1960;23:587–598. [PMC free article] [PubMed] [Google Scholar]
  4. DUFOUR A. P., KNIGHT R. A., HARRIS H. W. GENETICS OF ISONIAZID METABOLISM IN CAUCASIAN, NEGRO, AND JAPANESE POPULATIONS. Science. 1964 Jul 24;145(3630):391–391. [PubMed] [Google Scholar]
  5. Das K. M., Eastwood M. A. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):514–520. doi: 10.1002/cpt1975185part1514. [DOI] [PubMed] [Google Scholar]
  6. Das K. M., Eastwood M. A., McManus J. P., Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973 Sep 6;289(10):491–495. doi: 10.1056/NEJM197309062891001. [DOI] [PubMed] [Google Scholar]
  7. Degowin R. L., Eppes R. B., Powell R. D., Carson P. E. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull World Health Organ. 1966;35(2):165–179. [PMC free article] [PubMed] [Google Scholar]
  8. EVANS D. A., DAVISON K., PRATT R. T. THE INFLUENCE OF ACETYLATOR PHENOTYPE ON THE EFFECTS OF TREATING DEPRESSION WITH PHENELZINE. Clin Pharmacol Ther. 1965 Jul-Aug;6:430–435. doi: 10.1002/cpt196564430. [DOI] [PubMed] [Google Scholar]
  9. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. EVANS D. A., WHITE T. A. HUMAN ACETYLATION POLYMORPHISM. J Lab Clin Med. 1964 Mar;63:394–403. [PubMed] [Google Scholar]
  11. Ellard G. A. Absorption, metabolism and excretion of di(rho-aminophenyl) sulphone (dapsone) and di(rho-aminophenyl) sulphoxide in man. Br J Pharmacol Chemother. 1966 Jan;26(1):212–217. doi: 10.1111/j.1476-5381.1966.tb01823.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Elson J., Strong J. M., Lee W. K., Atkinson A. J., Jr Antiarrhythmic potency of N-acetylprocainamide. Clin Pharmacol Ther. 1975 Feb;17(2):134–140. doi: 10.1002/cpt1975172134. [DOI] [PubMed] [Google Scholar]
  13. Evans D. A. An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969 Dec;6(4):405–407. doi: 10.1136/jmg.6.4.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. FRYMOYER J. W., JACOX R. F. INVESTIGATION OF THE GENETIC CONTROL OF SULFADIAZINE AND ISONIAZID METABOLISM IN THE RABBIT. J Lab Clin Med. 1963 Dec;62:891–904. [PubMed] [Google Scholar]
  15. Frislid K., Berg M., Hansteen V., Lunde P. K. Comparison of the acetylation of procainamide and sulfadimidine in man. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):433–438. doi: 10.1007/BF00606561. [DOI] [PubMed] [Google Scholar]
  16. Gelber R., Peters J. H., Gordon G. R., Glazko A. J., Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225–238. doi: 10.1002/cpt1971122part1225. [DOI] [PubMed] [Google Scholar]
  17. Glazko A. J., Dill W. A., Montalbo R. G., Holmes E. L. A new analytical procedure for dapsone. Application to blood-level and urinary-excretion studies in normal men. Am J Trop Med Hyg. 1968 May;17(3):465–473. [PubMed] [Google Scholar]
  18. Kutt H., Winters W., McDowell F. H. Depression of prahydroxylation of diphenylhydantoin by antituberculosis chemotherapy. Neurology. 1966 Jun;16(6):594–602. doi: 10.1212/wnl.16.6.594. [DOI] [PubMed] [Google Scholar]
  19. Lower G. M., Jr, Bryan G. T. Enzymatic N-acetylation of carcinogenic aromatic amines by liver cytosol of species displaying different organ susceptibilities. Biochem Pharmacol. 1973 Jul 1;22(13):1581–1588. doi: 10.1016/0006-2952(73)90024-5. [DOI] [PubMed] [Google Scholar]
  20. Mattila M. J., Tiitinen H., Alhava E. Acetylation pattern of different sulphonamides in rapid and slow isoniazid inactivators. Ann Med Exp Biol Fenn. 1969;47(4):308–315. [PubMed] [Google Scholar]
  21. Murray J. F., Jr, Gordon G. R., Peters J. H. A chromatographic-fluorometric procedure for the determination of nanogram quantities of antileprotic sulfones. J Lab Clin Med. 1971 Sep;78(3):464–471. [PubMed] [Google Scholar]
  22. Perry H. M., Jr, Tan E. M., Carmody S., Sakamoto A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med. 1970 Jul;76(1):114–125. [PubMed] [Google Scholar]
  23. Peters J. H., Gordon G. R., Colwell W. T., Jr The fluorometric measurement of 4,4'-diaminodiphenyl sulfone and its acetylated derivatives in plasma and urine. J Lab Clin Med. 1970 Aug;76(2):338–348. [PubMed] [Google Scholar]
  24. Reidenberg M. M., Drayer D. E., Levy M., Warner H. Polymorphic acetylation procainamide in man. Clin Pharmacol Ther. 1975 Jun;17(6):722–730. doi: 10.1002/cpt1975176722. [DOI] [PubMed] [Google Scholar]
  25. Reidenberg M. M., Drayer D., DeMarco A. L., Bello C. T. Hydralazine elimination in man. Clin Pharmacol Ther. 1973 Nov-Dec;14(6):970–977. doi: 10.1002/cpt1973146970. [DOI] [PubMed] [Google Scholar]
  26. SUNAHARA S., URANOM, OGAWAM Genetical and geographic studies on isoniazid inactivation. Science. 1961 Nov 10;134(3489):1530–1531. doi: 10.1126/science.134.3489.1530. [DOI] [PubMed] [Google Scholar]
  27. Scott E. M., Wright R. C., Weaver D. D. The discrimination of phenotypes for rate of disappearance of isonicotinoyl hydrazide from serum. J Clin Invest. 1969 Jul;48(7):1173–1176. doi: 10.1172/JCI106081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Zacest R., Koch-Weser J. Relation of hydralazine plasma concentration to dosage and hypotensive action. Clin Pharmacol Ther. 1972 May-Jun;13(3):420–425. doi: 10.1002/cpt1972133420. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES